Baidu
map

CLIN CANCER RES:抗CTLA4治疗对过继TIL疗法治疗转移性黑色素瘤患者的影响

2018-09-21 MedSci MedSci原创

使用肿瘤浸润淋巴细胞进行过继细胞治疗在转移性黑色素瘤患者中均有临床疗效。近年来免疫检查点抑制剂得到广泛应用,其对肿瘤浸润淋巴细胞过继治疗的影响以及两种治疗方案的合理顺序尚需探索。CLIN CANCER RES近期发表了一篇文章研究这一问题。

使用肿瘤浸润淋巴细胞(TIL)进行过继细胞治疗在转移性黑色素瘤患者中均有临床疗效。近年来免疫检查点抑制剂得到广泛应用,其对肿瘤浸润淋巴细胞过继治疗的影响以及两种治疗方案的合理顺序尚需探索。CLIN CANCER RES近期发表了一篇文章研究这一问题。

共有74例转移性黑色素瘤患者接受了自体肿瘤浸润淋巴细胞治疗并评估治疗反应,总生存情况及无进展生存情况。作者还评估了与治疗反应有关的免疫学因素。队列的总缓解率为42%:未接受过免疫检查点抑制剂治疗的患者为47%,仅接受过抗CTLA4治疗的患者为38%,接受过抗PD-1治疗的患者为33%。中位总生存时间为17.3个月,未接受过CTLA4治疗的患者为24.6个月,接受过CTLA4阻断治疗的患者为8.6个月。后者肿瘤浸润淋巴细胞浸润较少且缓解持续时间较短。肿瘤浸润淋巴细胞浸润程度高,CD8细胞占主要成分以及表达BTLA与未接受抗CTLA4治疗患者的治疗反应增强有关,但是抗CTLA4治疗后复发的患者无此效果。血浆基线IL-9水平可以预测过继细胞治疗反应。

文章最后认为,在肿瘤浸润淋巴细胞过继治疗前接受抗CTLA4治疗有负面效果,基线IL-9水平可以作为预测工具以选择合适的免疫治疗顺序。

原始出处:
Marie-Andree Forget,Cara Haymaker,et al.Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma:Response,Impact of Anti-CTLA4,and Biomarker to Predict Clinical Outcome.CLIN CANCER RES.September 2018 doi:10.1158/1078-0432.CCR-17-3649

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680560, encodeId=926e1680560a4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Apr 15 13:55:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361572, encodeId=beac13615e279, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93445, encryptionId=bcd093445b5, topicName=转移性黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386422, encodeId=7b5e1386422cc, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558926, encodeId=e3231558926d9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564935, encodeId=fa20156493535, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346092, encodeId=02253460927b, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Sep 22 07:41:08 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
    2019-04-15 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680560, encodeId=926e1680560a4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Apr 15 13:55:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361572, encodeId=beac13615e279, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93445, encryptionId=bcd093445b5, topicName=转移性黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386422, encodeId=7b5e1386422cc, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558926, encodeId=e3231558926d9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564935, encodeId=fa20156493535, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346092, encodeId=02253460927b, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Sep 22 07:41:08 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680560, encodeId=926e1680560a4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Apr 15 13:55:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361572, encodeId=beac13615e279, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93445, encryptionId=bcd093445b5, topicName=转移性黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386422, encodeId=7b5e1386422cc, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558926, encodeId=e3231558926d9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564935, encodeId=fa20156493535, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346092, encodeId=02253460927b, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Sep 22 07:41:08 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680560, encodeId=926e1680560a4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Apr 15 13:55:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361572, encodeId=beac13615e279, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93445, encryptionId=bcd093445b5, topicName=转移性黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386422, encodeId=7b5e1386422cc, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558926, encodeId=e3231558926d9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564935, encodeId=fa20156493535, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346092, encodeId=02253460927b, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Sep 22 07:41:08 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1680560, encodeId=926e1680560a4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Apr 15 13:55:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361572, encodeId=beac13615e279, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93445, encryptionId=bcd093445b5, topicName=转移性黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386422, encodeId=7b5e1386422cc, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558926, encodeId=e3231558926d9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564935, encodeId=fa20156493535, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346092, encodeId=02253460927b, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Sep 22 07:41:08 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1680560, encodeId=926e1680560a4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Apr 15 13:55:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361572, encodeId=beac13615e279, content=<a href='/topic/show?id=bcd093445b5' target=_blank style='color:#2F92EE;'>#转移性黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93445, encryptionId=bcd093445b5, topicName=转移性黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386422, encodeId=7b5e1386422cc, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558926, encodeId=e3231558926d9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564935, encodeId=fa20156493535, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Sep 23 00:55:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346092, encodeId=02253460927b, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Sep 22 07:41:08 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
    2018-09-22 kafei

    了解一下谢谢

    0

相关资讯

免疫治疗用于黑色素瘤新辅助和辅助治疗的新近进展

由中国临床肿瘤学会(CSCO)和北京大学肿瘤医院联合举办的“CSCO 2018第四届北京黑色素瘤国际研讨会”在北京成功召开。本次会议云集了国际黑色素瘤领域的顶尖专家学者,与中国关注黑色素瘤事业发展的临床医生、科研人员一道,分享交流全球的最新研究进展,切磋探讨黑色素瘤诊治和研究中的实际问题,为我国学者提供了一个广泛交流与学习的平台。【肿瘤资讯】有幸邀请到GustaveRoussy癌症研究所Egger

CLIN CANCER RES:PHIP拷贝数作为皮肤黑色素瘤的预后及进展标志

之前的研究表明PHIP在调节黑色素瘤转移的过程中发挥了重要作用。CLIN CANCER RES近期发表了一篇文章,研究PHIP拷贝数在黑色素瘤进展中的作用。

PNAS重磅:100%的黑色素瘤完全消失!只需这两种药物联合使用!

成功的癌症免疫疗法需要激活先天免疫受体以促进树突细胞(DC)成熟,抗原呈递,共刺激分子的上调和细胞因子分泌,最终诱导肿瘤抗原特异性细胞毒性T淋巴细胞(CTL)的活化,达到杀灭肿瘤的效果。一次偶然的化学合成产生了一种名为Diprovocim化合物,由于其特殊的药理效应引起了德克萨斯大学西南医学中心Bruce Beutler研究团队的注意,接下来的研究发现这种药物作为Toll样受体(TLR)1 / T

身上有胎记和痣?这些你需要警惕了

近日,河南20岁小伙魏尚子因一片胎记住院,医生说是“癌”。帅气的魏尚子新婚不久,右肩部那颗“蝇子屎”大小的胎记自出生起就陪伴着他,不痛不痒从来没有在意过,但自去年开始,这颗伴随着他成长的胎记竟开始疯狂生长,从豆粒大小到如今鸡蛋一般大,且发作起来后牵动全身都疼痛难忍,无奈之下只得住进了郑州的大医院。

Lancet oncol:Encorafenib联合binimetinib治疗BRAF突变型黑色素瘤总体存活率效益显著

COLUMBUS试验研究encorafenib联合binimetinib和单独应用encorafenib对比vemurafenib用于携带BRAF[V600]突变的黑色素瘤患者提高无进展存活期的效果。现研究人员对总体存活率的次要结点结果进行汇总。COLUMBUS试验是在28个国家的162家医院中进行的包含两部分的随机的、开放性的3期研究,招募年满18岁的病理确诊的局部晚期不可手术切除的或已转移的皮

Omid Hamid教授:黑色素瘤免疫治疗一线应用疗效更佳

由北京大学肿瘤医院和CSCO黑色素瘤专家委员会主办的2018第四届北京黑色素瘤国际研讨会在京成功举办。20余位国际级顶尖专家齐聚一堂,与国内医生共同探讨黑色素瘤治疗热点和焦点话题。肿瘤资讯特邀Omid Hamid教授共同探讨免疫治疗在黑色素瘤中的应用。

Baidu
map
Baidu
map
Baidu
map